BRPI0511479C1 - molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis - Google Patents

molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis

Info

Publication number: BRPI0511479C1
Authority: BR; Brazil
Prior art keywords: molecule; binding; functional variant; binding molecule; nucleic acid
Prior art date: 2004-05-27

Application number

Other languages

English (en)

Original Assignee

Crucell Holland Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-27

Filing date

2005-05-26

Publication date

2021-05-25

2005-05-26 Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv

2007-12-26 Publication of BRPI0511479A publication Critical patent/BRPI0511479A/pt

2019-01-29 Publication of BRPI0511479B1 publication Critical patent/BRPI0511479B1/pt

2021-05-25 Publication of BRPI0511479C1 publication Critical patent/BRPI0511479C1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Oncology (AREA)
Plant Pathology (AREA)

BRPI0511479-9 2004-05-27 2005-05-26 molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis BRPI0511479C1 (pt)

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
US57502304P	2004-05-27	2004-05-27
EP2004050943		2004-05-27
EPPCT/EP2004/050943		2004-05-27
US60/575,203		2004-05-27
EP2004051661		2004-07-29
EPPCT/EP2004/051661		2004-07-29
EPPCT/EP2004/052286		2004-09-23
EP2004052286		2004-09-23
EP2004052772		2004-11-03
EPPCT/EP2004/052772		2004-11-03
EP2005050310		2005-01-25
EPPCT/EP2005/050310		2005-01-25
EP2005050953		2005-03-03
EPPCT/EP2005/050953		2005-03-03
PCT/EP2005/052410 WO2005118644A2 (en)	2004-05-27	2005-05-26	Binding molecules capable of neutralizing rabies virus and uses thereof

Publications (3)

Publication Number	Publication Date
BRPI0511479A BRPI0511479A (pt)	2007-12-26
BRPI0511479B1 BRPI0511479B1 (pt)	2019-01-29
BRPI0511479C1 true BRPI0511479C1 (pt)	2021-05-25

Family

ID=34968690

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0511479-9 BRPI0511479C1 (pt)	2004-05-27	2005-05-26	molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis

Country Status (22)

Country	Link
US (5)	US7579446B2 (pt)
EP (3)	EP2314620B1 (pt)
JP (1)	JP4768730B2 (pt)
KR (2)	KR101228157B1 (pt)
CN (5)	CN102212132A (pt)
AT (1)	ATE501171T1 (pt)
AU (1)	AU2005250163B2 (pt)
BR (1)	BRPI0511479C1 (pt)
CA (1)	CA2568162C (pt)
CU (1)	CU23719A3 (pt)
CY (1)	CY1111550T1 (pt)
DK (1)	DK1749029T3 (pt)
EA (1)	EA010785B1 (pt)
ES (2)	ES2426725T3 (pt)
HR (3)	HRP20110320T1 (pt)
IL (3)	IL179586A (pt)
MX (1)	MXPA06013482A (pt)
NZ (2)	NZ580607A (pt)
PL (3)	PL1749029T3 (pt)
PT (3)	PT2314621E (pt)
RS (2)	RS53269B (pt)
WO (1)	WO2005118644A2 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
DE60317677T2 (de) *	2002-06-13	2008-10-30	Crucell Holland B.V.	Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EP1539235A2 (en)	2002-07-01	2005-06-15	Human Genome Sciences, Inc.	Antibodies that specifically bind to reg iv
DK2314629T4 (da)	2002-07-18	2023-02-06	Merus Nv	Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
WO2004106375A1 (en)	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Fab library for the preparation of anti vegf and anti rabies virus fabs
EP2322547A1 (en)	2003-06-25	2011-05-18	Crucell Holland B.V.	Myeloid cell-specific lectin
SG128680A1 (en) *	2003-07-22	2007-01-30	Crucell Holland Bv	Binding molecules against sars-coronavirus and uses thereof
EP2314620B1 (en)	2004-05-27	2013-06-05	Crucell Holland B.V.	Method of identifying binding molecules capable of neutralizing rabies virus
JP4852046B2 (ja) *	2004-10-12	2012-01-11	クルセルホランドベーヴェー	癌の治療及び検出に用いる結合分子
WO2006120230A2 (en)	2005-05-12	2006-11-16	Crucell Holland B.V.	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CA2622603C (en) *	2005-09-15	2014-06-17	Crucell Holland B.V.	Method for preparing immunoglobulin libraries
WO2007038407A2 (en)	2005-09-23	2007-04-05	The Regents Of The University Of California	Compositions and methods for treating nervous system disorders
MX2008014978A (es)	2006-06-06	2008-12-09	Crucell Holland Bv	Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
CA2881717C (en)	2006-06-06	2018-06-12	Cecilia Anna Wilhelmina Geuijen	Human binding molecules having killing activity against staphylococci and uses thereof
EP2450377A1 (en)	2006-09-07	2012-05-09	Crucell Holland B.V.	Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
JP5410985B2 (ja) *	2006-12-05	2014-02-05	クルセルホランドベーヴェー	液体抗狂犬病抗体製剤
BRPI0813645A2 (pt)	2007-06-25	2014-12-30	Esbatech Alcon Biomed Res Unit	Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010132532A1 (en)	2009-05-15	2010-11-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	B cell surface reactive antibodies
US8821879B2 (en)	2009-09-04	2014-09-02	Xoma Technology Ltd.	Anti-botulism antibody coformulations
HUE031571T2 (en) *	2009-10-02	2017-07-28	Univ California	Monoclonal antibodies
CN101696242B (zh) *	2009-10-26	2011-12-28	中国人民解放军南京军区军事医学研究所	人源抗狂犬病毒中和抗体Fab及其制备方法和应用
CN103596975A (zh) *	2010-01-04	2014-02-19	印度免疫有限公司	针对狂犬病病毒的重组人二价双链抗体及其用途
EP2894220B1 (en)	2010-02-19	2017-11-22	Japan Science and Technology Agency	Human abzyme
PT3345615T (pt)	2010-03-01	2020-01-17	Bayer Healthcare Llc	Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
PT3904391T (pt)	2010-03-10	2024-10-14	Genmab As	Anticorpos monoclonais contra c-met
EP2582727B8 (en) *	2010-06-16	2017-04-19	University of Pittsburgh- Of the Commonwealth System of Higher Education	Antibodies to endoplasmin and their use
KR101388680B1 (ko) *	2011-03-18	2014-04-28	(주)셀트리온	광견병 바이러스를 중화시킬 수 있는 결합 분자
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
KR101495019B1 (ko)	2011-09-30	2015-02-24	(주)셀트리온	광견병 바이러스를 중화시킬 수 있는 결합 분자
US9248181B2 (en)	2012-04-20	2016-02-02	Merus B.V.	Methods and means for the production of Ig-like molecules
CN102924571A (zh) *	2012-10-29	2013-02-13	复旦大学	狂犬病毒糖蛋白与核蛋白的抗原表位多肽及其筛选、鉴定方法与应用
WO2015088256A1 (ko) *	2013-12-12	2015-06-18	(주)셀트리온	광견병 바이러스를 중화시킬 수 있는 결합 분자
CN103954777A (zh) *	2014-05-20	2014-07-30	北京凯思百奥科技发展有限公司	一种狂犬病病毒单克隆抗体及其应用
RU2549971C1 (ru) *	2014-07-01	2015-05-10	Федеральное казённое учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека	Способ консервации иммунопероксидазного конъюгата
CN104761640A (zh) *	2015-02-03	2015-07-08	中国食品药品检定研究院	具有中和活性的抗狂犬病病毒单克隆抗体的制备及应用
EP3256165B1 (en) *	2015-02-13	2021-07-14	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind ctla4
US10722571B2 (en) *	2015-06-10	2020-07-28	Celltrion Inc.	Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto
CN109069627A (zh)	2016-01-14	2018-12-21	纪念斯隆-凯特琳癌症中心	对foxp3衍生肽特异性的t细胞受体样抗体
JOP20190248A1 (ar) *	2017-04-21	2019-10-20	Amgen Inc	بروتينات ربط مولد ضد trem2 واستخداماته
RU2718835C2 (ru) *	2017-12-29	2020-04-15	Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ)	Нейтрализующее моноклональное антитело, связывающееся с гликопротеином g вируса бешенства, фрагменты днк, кодирующие указанное антитело, и антигенсвязывающий фрагмент
WO2019227039A1 (en) *	2018-05-24	2019-11-28	Lankenau Institute For Medical Research	Compositions comprising antibodies to rabies virus and the uses thereof
WO2020029860A1 (zh) *	2018-08-09	2020-02-13	北京智仁美博生物科技有限公司	针对狂犬病病毒的双特异性抗体及其用途
CA3136281C (en) *	2019-05-30	2024-06-25	Shandong Boan Biotechnology Co., Ltd.	Antibody or chimeric antigen receptor which targets claudin 18.2
CN111171145B (zh) *	2020-01-21	2021-11-05	兰州生物制品研究所有限责任公司	一种抗狂犬病病毒单克隆抗体、制备方法及用途
MX2022014598A (es) *	2020-05-26	2023-03-31	Regeneron Pharma	Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
WO2022217054A1 (en) *	2021-04-09	2022-10-13	Sorrento Therapeutics, Inc.	Antigen binding proteins that bind ror1
CN114397453B (zh) *	2022-03-25	2022-06-07	江苏美克医学技术有限公司	新型冠状病毒突变株的检测试剂盒及其应用
CN118290572B (zh) *	2023-09-19	2026-04-07	军事科学院军事医学研究院军事兽医研究所	抗狂犬病病毒全人源抗体及其组合物与应用
CN119930826A (zh) *	2023-11-02	2025-05-06	重庆精准生物产业技术研究院有限公司	针对psca的全人源单链抗体及其应用
CN117777282B (zh) *	2023-12-07	2025-03-04	兰州生物制品研究所有限责任公司	一种抗狂犬病病毒中和抗体及其制备和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
ATE99958T1 (de) *	1989-06-08	1994-01-15	Wistar Inst	Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
US6248574B1 (en)	1989-12-13	2001-06-19	Avigdor Shaffermann	Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
DE4006630A1 (de)	1990-03-03	1991-09-12	Behringwerke Ag	Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
NL9101953A (nl)	1991-11-21	1993-06-16	Seed Capital Investments	Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en)	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
DK0934526T3 (da)	1996-10-08	2003-05-05	Bisys B V U	Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
HK1048138B (zh)	1999-04-15	2009-06-12	荷兰克鲁塞尔公司	用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US20040013672A1 (en) *	2000-05-16	2004-01-22	Thomas Jefferson University	Recombinant antibodies, and compositions and methods for making and using the same
US7071319B2 (en) *	2000-05-16	2006-07-04	Thomas Jefferson University	Recombinant antibodies, and compositions and methods for making and using the same
ES2257560T3 (es)	2001-06-15	2006-08-01	Crucell Holland B.V.	Fagos quimericos.
WO2003016501A2 (en) *	2001-08-21	2003-02-27	Thomas Jefferson University	Recombinant antibodies, and compositions and methods for making and using the same
DE60317677T2 (de)	2002-06-13	2008-10-30	Crucell Holland B.V.	Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
DK2314629T4 (da) *	2002-07-18	2023-02-06	Merus Nv	Rekombinant produktion af blandinger af antistoffer
US20100069614A1 (en) *	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
EP2322547A1 (en)	2003-06-25	2011-05-18	Crucell Holland B.V.	Myeloid cell-specific lectin
SG128680A1 (en) *	2003-07-22	2007-01-30	Crucell Holland Bv	Binding molecules against sars-coronavirus and uses thereof
ES2367027T3 (es)	2004-02-27	2011-10-27	Inserm (Institut National De La Santé Et De La Recherche Medicale)	Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
EP2314620B1 (en) *	2004-05-27	2013-06-05	Crucell Holland B.V.	Method of identifying binding molecules capable of neutralizing rabies virus
US8106170B2 (en)	2004-11-11	2012-01-31	Crucell Holland B.V.	Compositions against SARS-coronavirus and uses thereof
CA2591665C (en)	2004-12-20	2015-05-05	Crucell Holland B.V.	Binding molecules capable of neutralizing west nile virus and uses thereof
EP1871803B1 (en)	2005-04-18	2013-02-20	Yeda Research And Development Company Limited	Stabilized anti-hepatitis b (hbv) antibody formulations
WO2006120230A2 (en)	2005-05-12	2006-11-16	Crucell Holland B.V.	Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006136601A1 (en)	2005-06-23	2006-12-28	Crucell Holland B.V.	Optimization of west nile virus antibodies
CA2643838A1 (en) *	2006-02-27	2007-09-07	Elan Pharmaceuticals, Inc.	Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
CA2881717C (en) *	2006-06-06	2018-06-12	Cecilia Anna Wilhelmina Geuijen	Human binding molecules having killing activity against staphylococci and uses thereof
MX2008014978A (es) *	2006-06-06	2008-12-09	Crucell Holland Bv	Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
EP2450377A1 (en) *	2006-09-07	2012-05-09	Crucell Holland B.V.	Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
JP5410985B2 (ja)	2006-12-05	2014-02-05	クルセルホランドベーヴェー	液体抗狂犬病抗体製剤

2005
- 2005-05-26 EP EP10180375.7A patent/EP2314620B1/en not_active Expired - Lifetime
- 2005-05-26 BR BRPI0511479-9 patent/BRPI0511479C1/pt not_active IP Right Cessation
- 2005-05-26 EP EP10180398.9A patent/EP2314621B1/en not_active Expired - Lifetime
- 2005-05-26 CN CN2011100709086A patent/CN102212132A/zh active Pending
- 2005-05-26 RS RS20140221A patent/RS53269B/sr unknown
- 2005-05-26 NZ NZ580607A patent/NZ580607A/en not_active IP Right Cessation
- 2005-05-26 ES ES10180375T patent/ES2426725T3/es not_active Expired - Lifetime
- 2005-05-26 EA EA200602210A patent/EA010785B1/ru unknown
- 2005-05-26 PL PL05747901T patent/PL1749029T3/pl unknown
- 2005-05-26 PT PT101803989T patent/PT2314621E/pt unknown
- 2005-05-26 CN CN201110071403.1A patent/CN102139106B/zh not_active Expired - Fee Related
- 2005-05-26 EP EP05747901A patent/EP1749029B1/en not_active Expired - Lifetime
- 2005-05-26 PL PL10180398T patent/PL2314621T3/pl unknown
- 2005-05-26 AT AT05747901T patent/ATE501171T1/de active
- 2005-05-26 DK DK05747901.6T patent/DK1749029T3/da active
- 2005-05-26 NZ NZ550366A patent/NZ550366A/en not_active IP Right Cessation
- 2005-05-26 CN CN201110070883XA patent/CN102212131B/zh not_active Expired - Fee Related
- 2005-05-26 CN CN2005800172331A patent/CN1961002B/zh not_active Expired - Fee Related
- 2005-05-26 PT PT05747901T patent/PT1749029E/pt unknown
- 2005-05-26 ES ES10180398.9T patent/ES2468021T3/es not_active Expired - Lifetime
- 2005-05-26 RS RS20110240A patent/RS51847B/sr unknown
- 2005-05-26 KR KR1020067024277A patent/KR101228157B1/ko not_active Expired - Fee Related
- 2005-05-26 PT PT101803757T patent/PT2314620E/pt unknown
- 2005-05-26 WO PCT/EP2005/052410 patent/WO2005118644A2/en not_active Ceased
- 2005-05-26 MX MXPA06013482A patent/MXPA06013482A/es active IP Right Grant
- 2005-05-26 KR KR1020127030900A patent/KR101456770B1/ko not_active Expired - Fee Related
- 2005-05-26 AU AU2005250163A patent/AU2005250163B2/en not_active Ceased
- 2005-05-26 HR HR20110320T patent/HRP20110320T1/hr unknown
- 2005-05-26 PL PL10180375T patent/PL2314620T3/pl unknown
- 2005-05-26 CN CN201110070931.5A patent/CN102241769B/zh not_active Expired - Fee Related
- 2005-05-26 CA CA2568162A patent/CA2568162C/en not_active Expired - Fee Related
- 2005-05-26 JP JP2007513935A patent/JP4768730B2/ja not_active Expired - Fee Related
2006
- 2006-10-31 US US11/590,126 patent/US7579446B2/en not_active Expired - Lifetime
- 2006-11-26 IL IL179586A patent/IL179586A/en active IP Right Grant
- 2006-11-27 CU CU20060230A patent/CU23719A3/es not_active IP Right Cessation
2007
- 2007-10-29 US US11/980,237 patent/US20080070799A1/en not_active Abandoned
- 2007-10-29 US US11/978,742 patent/US7740852B2/en not_active Expired - Fee Related
2009
- 2009-07-06 US US12/459,661 patent/US8148497B2/en not_active Expired - Fee Related
- 2009-11-05 IL IL201970A patent/IL201970A/en active IP Right Grant
2010
- 2010-04-08 US US12/798,748 patent/US9005624B2/en not_active Expired - Fee Related
2011
- 2011-06-08 CY CY20111100548T patent/CY1111550T1/el unknown
2013
- 2013-04-18 IL IL225849A patent/IL225849A0/en active IP Right Grant
- 2013-08-07 HR HRP20130750TT patent/HRP20130750T1/hr unknown
2014
- 2014-05-08 HR HRP20140419TT patent/HRP20140419T1/hr unknown

Also Published As

Publication number	Publication date
CN1961002B (zh)	2011-05-18
CN102139106B (zh)	2014-10-08
CY1111550T1 (el)	2015-08-05
KR101456770B1 (ko)	2014-10-31
NZ550366A (en)	2009-11-27
RS51847B (sr)	2012-02-29
HRP20130750T1 (hr)	2013-10-11
US7579446B2 (en)	2009-08-25
HK1157680A1 (en)	2012-07-06
CN102212132A (zh)	2011-10-12
IL201970A (en)	2014-06-30
KR20130010130A (ko)	2013-01-25
IL179586A0 (en)	2007-05-15
ES2468021T3 (es)	2014-06-13
US20070072177A1 (en)	2007-03-29
EP2314621B1 (en)	2014-03-05
MXPA06013482A (es)	2007-03-01
US20100310572A1 (en)	2010-12-09
US9005624B2 (en)	2015-04-14
EP2314620B1 (en)	2013-06-05
US20080226652A1 (en)	2008-09-18
ES2426725T3 (es)	2013-10-24
CN102212131A (zh)	2011-10-12
HRP20140419T1 (hr)	2014-06-06
HK1094705A1 (en)	2007-04-04
IL179586A (en)	2013-06-27
AU2005250163B2 (en)	2011-08-25
WO2005118644A2 (en)	2005-12-15
CN102241769A (zh)	2011-11-16
CA2568162A1 (en)	2005-12-15
CN102139106A (zh)	2011-08-03
EP2314620A1 (en)	2011-04-27
KR101228157B1 (ko)	2013-01-31
DK1749029T3 (da)	2011-06-06
CU23719A3 (es)	2011-10-14
NZ580607A (en)	2011-05-27
CN1961002A (zh)	2007-05-09
EP2314621A1 (en)	2011-04-27
ATE501171T1 (de)	2011-03-15
CN102212131B (zh)	2013-05-08
EA200602210A1 (ru)	2007-04-27
PL2314621T3 (pl)	2014-08-29
PL1749029T3 (pl)	2011-08-31
WO2005118644A3 (en)	2006-03-09
US20080070799A1 (en)	2008-03-20
US7740852B2 (en)	2010-06-22
US8148497B2 (en)	2012-04-03
CN102241769B (zh)	2016-08-10
RS53269B (sr)	2014-08-29
JP2008508859A (ja)	2008-03-27
PT1749029E (pt)	2011-06-27
IL225849A0 (en)	2013-06-27
PT2314620E (pt)	2013-09-02
BRPI0511479A (pt)	2007-12-26
BRPI0511479B1 (pt)	2019-01-29
HK1159651A1 (en)	2012-08-03
JP4768730B2 (ja)	2011-09-07
HRP20110320T1 (hr)	2011-05-31
KR20070044807A (ko)	2007-04-30
US20100272724A1 (en)	2010-10-28
EA010785B1 (ru)	2008-10-30
EP1749029B1 (en)	2011-03-09
EP1749029A2 (en)	2007-02-07
PT2314621E (pt)	2014-06-23
AU2005250163A1 (en)	2005-12-15
PL2314620T3 (pl)	2013-11-29
CA2568162C (en)	2013-04-16

Publication	Publication Date	Title
BRPI0511479C1 (pt)	2021-05-25	molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
WO2007053189A3 (en)	2007-11-01	Compositions and methods for altering immune function
NZ543467A (en)	2008-07-31	The severe acute respiratory syndrome coronavirus
ATE536376T1 (de)	2011-12-15	Humanes bindungsmolekül gegen cd1a
WO2006067122A3 (en)	2007-08-23	Binding molecules capable of neutralizing west nile virus and uses thereof
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
WO2007095316A3 (en)	2008-03-27	Compositions and methods for oligonucleotide formulations
EA200870593A1 (ru)	2009-06-30	Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
CO6430436A2 (es)	2012-04-30	Inmunoconjugados dirigidos
WO2005012360A3 (en)	2005-09-29	Binding molecules against sars-coronavirus and uses thereof
BR112015031883A2 (pt)	2018-02-14	anti-pd-1 anticorpo e o uso dele
BRPI0506771A (pt)	2007-05-22	anticorpo, e, composição farmacêutica
BRPI0508931A (pt)	2007-08-14	ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico
EA200870594A1 (ru)	2009-06-30	Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
NO20081883L (no)	2008-06-11	Modulasjon av glukokortikoidreseptorekspresjon
WO2008070672A3 (en)	2009-04-16	Compositions and methods to treat cancer with cupredoxins and cpg rich dna
EA201001322A1 (ru)	2011-02-28	Вакцины против хламидиоза
IL187321A (en)	2013-06-27	Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments
ATE485517T1 (de)	2010-11-15	Verfahren zur identifizierung von polypeptid- targets
DE602006019475D1 (de)	2011-02-17	Verfahren zur mikrorna-identifikation und ihrer anwendungen bei der forschung und menschlichen gesundheit
WO2008108830A3 (en)	2008-10-30	Immunogenic and therapeutic compositions for streptococcus pyogenes
EA200800869A1 (ru)	2008-10-30	Модуляция экспрессии рецептора глюкагона
FI20011664A7 (fi)	2003-02-18	Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
BRPI0507960A (pt)	2007-07-17	métodos terapêuticos empregando precursores de óxido nìtrico
ATE533501T1 (de)	2011-12-15	Verwendung des ped-faktors zur induktion von zellregenerierung

Legal Events

Date	Code	Title	Description
2012-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2017-09-19	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-03	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-07-10	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2018-08-28	B25D	Requested change of name of applicant approved	Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)
2018-11-06	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-01-15	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS.
2019-01-29	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/01/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2506 DE 15/01/2019,QUANTO AO ITEM (72).
2020-12-22	B25G	Requested change of headquarter approved	Owner name: JANSSEN VACCINES AND PREVENTION B.V. (NL)
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-03-21	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 18A ANUIDADE.
2023-07-11	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2724 DE 21-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.